Compile Data Set for Download or QSAR
Report error Found 49 Enz. Inhib. hit(s) with all data for entry = 50041955
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419384(CHEMBL1916289)
Affinity DataIC50: 13nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419381(CHEMBL1916284)
Affinity DataIC50: 25nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419356(CHEMBL1916288)
Affinity DataIC50: 25nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419372(CHEMBL1916271)
Affinity DataIC50: 79nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 79nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 126nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419376(CHEMBL1916277)
Affinity DataIC50: 158nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419379(CHEMBL1916280)
Affinity DataIC50: 158nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419387(CHEMBL1916255)
Affinity DataIC50: 316nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50418334(CHEMBL1770298)
Affinity DataIC50: 398nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419380(CHEMBL1916283)
Affinity DataIC50: 501nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419373(CHEMBL1916272)
Affinity DataIC50: 501nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50418335(CHEMBL1770297)
Affinity DataIC50: 501nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419386(CHEMBL1916274)
Affinity DataIC50: 794nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419360(CHEMBL1916087)
Affinity DataIC50: 794nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419383(CHEMBL1916287)
Affinity DataIC50: 1.00E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419382(CHEMBL1916286)
Affinity DataIC50: 1.00E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419375(CHEMBL1916276)
Affinity DataIC50: 1.00E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419359(CHEMBL1916085)
Affinity DataIC50: 1.59E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419388(CHEMBL1916262)
Affinity DataIC50: 1.59E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419378(CHEMBL1916279)
Affinity DataIC50: 2.00E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419357(CHEMBL1916082)
Affinity DataIC50: 2.00E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419390(CHEMBL1916275)
Affinity DataIC50: 3.16E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419365(CHEMBL1916261)
Affinity DataIC50: 3.98E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419358(CHEMBL1916084)
Affinity DataIC50: 3.98E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419377(CHEMBL1916278)
Affinity DataIC50: 5.01E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419364(CHEMBL1916260)
Affinity DataIC50: 5.01E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419370(CHEMBL1916267)
Affinity DataIC50: 5.01E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419371(CHEMBL1916270)
Affinity DataIC50: 5.01E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419363(CHEMBL1916259)
Affinity DataIC50: 5.01E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419374(CHEMBL1916273)
Affinity DataIC50: 6.31E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419362(CHEMBL1916258)
Affinity DataIC50: 6.31E+3nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419356(CHEMBL1916288)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419356(CHEMBL1916288)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP3A4More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419356(CHEMBL1916288)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP1A2More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419356(CHEMBL1916288)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C19More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C19More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419356(CHEMBL1916288)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C9More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP2C9More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419355(CHEMBL1916282)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of CYP1A2More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419367(CHEMBL1916264)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419366(CHEMBL1916263)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419385(CHEMBL1916086)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419389(CHEMBL1916268)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419361(CHEMBL1916257)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419368(CHEMBL1916265)
Affinity DataIC50: 1.58E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetfMet-Leu-Phe receptor(Human)
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50419369(CHEMBL1916266)
Affinity DataIC50: 2.00E+4nMAssay Description:Antagonist activity at human FPR1 in human neutrophils assessed as inhibition of fMLF-stimulated intracellular calcium mobilisation by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed